Product Approval (ANDA)
Aurobindo Pharma Receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid
NSE
auropharma
BSE
524804
Aurobindo Pharma has received USFDA final approval for Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), used in the treatment of urea cycle disorders (UCDs), with an estimated market size of US$50.2 million.
PRICE-SENSITIVE TRIGGER
Event: USFDA Final Approval
Type: Product Approval (ANDA)
Impact: Positive
Immediate Effect: Enhances product pipeline and strengthens US generics portfolio
Financial Snapshot
- Market Size: ~US$50.2 million (IQVIA MAT Feb 2026)
- Total ANDA Approvals:
- 579 approvals
- 556 final approvals
- 23 tentative approvals
Highlights
Strong pipeline expansion in specialty + niche therapies
What Happened ?
Aurobindo Pharma announced:
- Final approval from USFDA
- Product: Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL)
- Equivalent to reference drug: Ravicti
Additional details:
- Manufactured at Unit-III facility
- Immediate launch planned
key highlights
- Used for:
- Chronic management of Urea Cycle Disorders (UCDs)
- Acts as:
- Nitrogen-binding agent
- Why this matters:
- Niche therapy → limited competition
- Better margins vs plain generics
Strategic Significance
- Strengthens US generics + specialty portfolio
- Entry into high-value niche segment
- Improves revenue diversification
- Enhances pipeline visibility
Insight:
Specialty approvals like this often deliver better margins than commoditized generics.
Risk Analysis
Key Risks
- Pricing pressure in US generics market
- Competition from other ANDA players
- Regulatory scrutiny
Worst Case Scenario
Lower-than-expected market share due to competition or pricing erosion
Risk Level: Medium
Company Commentary
- Focus remains on:
- Expanding regulated market portfolio
- Strengthening USFDA-approved pipeline
(No direct quotes disclosed in filing)
Official Exchange Filing: Aurobindo Pharma Limited